Manejo de las úlceras corneales neurotróficas con Cacicol®- ReGeneraTing Agent: serie de casos
- L. Salazar-Quiñones 12
- M. Molero-Senosiáin 2
- S. Aguilar-Munoa 23
- J.A. Gegúndez-Fernández 2
- D. Díaz-Valle 2
- A.M. Muñoz-Hernández 2
- J.M. Benítez-del-Castillo 2
-
1
Hospital General de Ciudad Real
info
-
2
Hospital Clínico San Carlos de Madrid
info
-
3
Moorfields Eye Hospital NHS Foundation Trust
info
ISSN: 0365-6691
Year of publication: 2020
Volume: 95
Issue: 9
Pages: 421-428
Type: Article
More publications in: Archivos de la Sociedad Española de Oftalmologia
Abstract
Purpose Neurotrophic corneal ulcers are difficult to treat, and the conventional treatment often results in failure. A new matrix regenerating agent (“ReGeneraTing Agents”), Cacicol® (Laboratoires Théa), has demonstrated good results over the last few years. Therefore, the aim of this study was to evaluate the response to Cacicol® in a series of cases with neurotrophic corneal ulcers. Methods Retrospective case series looking at 11 patients with corneal ulcers unresponsive to conventional therapy that underwent treatment with Cacicol®. One cycle included 1 drop every two days for 5 days. Results The range of conventional therapy prior to Cacicol® was 0-91 days. On introducing Cacicol® 82% (9/11) of the cases were cured, and 18% (2/11) failed, requiring an amniotic membrane transplant or penetrating keratoplasty. The healing only required one cycle of Cacicol® in 67% (6/9) of the patients. More than one cycle of Cacicol® was needed in 45% (5/11) patients. One corneal bacterial ulcer responded favourably and one case related to Acanthamoeba did not respond. Most of the patients improved or maintained their visual acuity. Conclusion Cacicol® was a useful therapy in a high number of difficult neurotrophic corneal ulcers, including corneal infections. Some cases may require more than one cycle of Cacicol® or used as first-line treatment in order to achieve the desired result.